Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$6.87B
sum of reported positions
Reported positions
67
Changes vs prior quarter
67
19 new · 15 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 102 measured positions in 8 quarters, the typical new or larger position finished +2.4 pts against the S&P 500 and 53% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 3.39M | $509M | 7.4% | |
| 9.34M | $360M | 5.2% | |
| 4.74M | $254M | 3.7% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $6.12B | $6.87B |
| Positions | 63 | 67 |
| Biggest line | — | Guardant Health 7% |
| 4.3M |
| $250M |
| 3.6% |
| 825K | $248M | 3.6% |
| 2M | $246M | 3.6% |
| 3.67M | $231M | 3.4% |
NUVALENT INC | 1.78M | $220M | 3.2% |
| 4M | $210M | 3.1% |
| 19.7M | $193M | 2.8% |
| 3.31M | $189M | 2.8% |
| 7.74M | $188M | 2.7% |
| 1.93M | $183M | 2.7% |
| 6.35M | $179M | 2.6% |
| 2.2M | $174M | 2.5% |
| 12.2M | $172M | 2.5% |
| 4M | $172M | 2.5% |
| 700K | $171M | 2.5% |
| 5.65M | $155M | 2.3% |
| 7M | $136M | 2.0% |
| 3.6M | $132M | 1.9% |
| 4.2M | $131M | 1.9% |
| 2.75M | $129M | 1.9% |
| 1.83M | $125M | 1.8% |
| 4.1M | $122M | 1.8% |
Xencor Inc (XNCR)
594K shares
Inventiva (IVA)
1.22M → 800K shares (−35%)
Geron (GERN)
31.7M shares in Q1 2026
SPDR SERIES TRUST · PUT
10M shares in Q1 2026
APELLIS PHARMACEUTICALS INC
4.53M shares in Q1 2026
ENGENE HOLDINGS INC
4.38M shares in Q1 2026
CENTESSA PHARMACEUTICALS PLC
3.16M shares in Q1 2026
Larimar Therapeutics (LRMR)
1.5M shares in Q1 2026
CYBIN INC
1.31M shares in Q1 2026
Janux Therapeutics (JANX)
1.19M shares in Q1 2026
SOLENO THERAPEUTICS INC
1.08M shares in Q1 2026
TERNS PHARMACEUTICALS INC
1.07M shares in Q1 2026
Bridgebio Pharma (BBIO)
841K shares in Q1 2026
ANI Pharmaceuticals, Inc. (ANIP)
600K shares in Q1 2026
Crescent Biopharma (CBIO)
454K shares in Q1 2026
APOGEE THERAPEUTICS INC
285K shares in Q1 2026
Billiontoone (BLLN)
50K shares in Q1 2026
